Change of serum lipid profiles during antiviral therapy in chronic hepatitis C
- VernacularTitle:Элэгний архаг С вирүсийн эмчилгээ өвчтөний цусан дахь өөх тосны түвшинд нөлөөлөх нь
- Author:
Batbold B
1
;
Gantsetseg G
2
;
Tulgaa L
1
;
Ganchimeg D
1
;
Sodnomtsogt L
1
;
Chia-Yen D
3
Author Information
1. Institute of Medical Sciences named after Shagdarsuren T., Mongolia
2. Mongolian Association of Family Medicine Specialists
3. Kaohsiung Medical University, Taiwan
- Publication Type:Journal Article
- Keywords:
HCV;
CHC;
Peg-Interferon;
Lipid profiles;
liver fibrosis
- From:Mongolian Medical Sciences
2018;186(4):14-22
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background :Low triglycerides and cholesterol was associated with hepatitis C virus (HCV) infection. Chronic HCV infection is the main cause of liver injury and it may influence to serum lipid levels. We aimed to evaluate the effect of antiviral treatment on the change of lipid profiles during interferon-based anti-HCV treatment.
Material and Methods :Totally 863 patients who completed the interferon-based antiviral therapy in Kaohsiung Medical University Hospital were included in this present study. The lipid profile measured and assessed in the baseline of the treatment and after 6 months of completion of the treatment.
Results :The most of the patients (81.2%) were achieved sustained virological response (SVR) by antiviral therapy. There was no significant difference between baseline triglycerides (TG) levels in the SVR group and non SVR groups. The TG levels at 6 months after completion of the treatment was significantly elevated in SVR group (102.9±57.0 mg/dL, p=0.0001) but did not elevated in non SVR group (94.5±45.6 mg/dL, p=0.690) compared with baseline TG levels.
After adjusting patients by four indexes for fibrosis (FIB4) in cut-off point 3.25, serum TG levels significantly increased in low FIB4 group (103.2±57.9 mg/dL, p=0.0001) but not in high FIB4 group (98.1±49.6 mg/dL, p=0.095) after 6 months end of the treatment. Serum TG level was increased greater in patients who had low FIB4 score and patients who achieved SVR (baseline 89.1±34.8 mg/dL; 6 months after treatment 104.3±59.3 mg/dL, paired T test p=0.0001).
Conclusion:The eradication of HCV is the main cause of the increase of lipids after Pegylated Interferon and Ribavirin treatment.
However advanced fibrosis also has an effect in increase of TG after the treatment.
- Full text:2018-186(4)-14-22.pdf
